BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published on August 5
mRNA technology has proven its commercial power with COVID vaccines, and now it's expanding into cancer treatment and other diseases. You're watching the birth of a new medical era.
BioNTech's doubled revenues provide the capital firepower needed for groundbreaking research. This financial success is fuelling the next wave of gene-based therapies across the entire sector.
These aren't random biotech picks. Each company was carefully selected by professional analysts for their role in the gene therapy revolution that's reshaping modern medicine.
BioNTech's massive vaccine success has created a financial powerhouse with the resources to revolutionise cancer treatment. This group captures companies at the forefront of mRNA and gene-based therapies, positioned to benefit as this technology expands beyond infectious diseases into oncology and other medical fields.
These are cutting-edge biotechnology companies specialising in genomic medicine, advanced drug delivery systems, and novel immunotherapies. They represent a growth-oriented, thematic investment opportunity that could disrupt traditional treatment approaches across multiple diseases.
Each company was handpicked by professional analysts for their role in the broader gene therapy ecosystem. With BioNTech's pivot into oncology proving the commercial viability of mRNA technology, these firms are positioned to capitalise on the expanding market for next-generation medical treatments.
Aggregate and breakdown of market capitalisation for the mRNA-focused basket called 'Beyond Vaccines: The mRNA Revolution'.
BNTX: $25.18B
MRNA: $10.74B
CVAC: $1.21B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 288.39% over the next year.
10 of 16 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+288.39%
